Biodexa Pharmaceuticals Plc
Open
$3.06
Prev. Close
$3.06
High
$3.06
Low
$3.03
Market Snapshot
-30.38
$1.45M
13
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 11 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 11 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Recently from Cashu
Biodexa Pharmaceuticals Plc: Awaiting Source Article to Produce Timely Summary
Source Missing: Biodexa Awaits Article Text to Produce Timely Summary Biodexa Pharmaceuticals Plc is currently unable to receive a Reuters-style summary because the source article text is missing. The…
Biodexa Pharmaceuticals Plc: Request for Content to Summarize.
I’m sorry, but it appears that you haven't provided the content you would like me to summarize. Please share the relevant details or text, and I will gladly create the summary for you.
Biodexa Pharmaceuticals: Pioneering Targeted Cancer Therapies with Innovative Drug Delivery Solutions
Biodexa Pharmaceuticals: Advancements in Targeted Cancer Therapies Biodexa Pharmaceuticals Plc is making significant strides in the field of targeted cancer therapies, focusing on its proprietary drug…
Summary Request for Biodexa Pharmaceuticals Plc Content
I apologize, but it seems there is no specific content provided for summarization. If you could share the text or details related to Biodexa Pharmaceuticals Plc, I would be glad to help you create a s…